tradingkey.logo

Ligand Pharmaceuticals Inc

LGND

169.830USD

+4.420+2.67%
終値 09/18, 16:00ET15分遅れの株価
3.30B時価総額
損失額直近12ヶ月PER

Ligand Pharmaceuticals Inc

169.830

+4.420+2.67%
詳細情報 Ligand Pharmaceuticals Inc 企業名
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
企業情報
企業コードLGND
会社名Ligand Pharmaceuticals Inc
上場日Nov 18, 1992
最高経営責任者「CEO」Mr. Todd C. Davis
従業員数68
証券種類Ordinary Share
決算期末Nov 18
本社所在地555 Heritage Drive, Suite 200
都市JUPITER
証券取引所NASDAQ Global Market Consolidated
United States of America
郵便番号33458
電話番号18585507500
ウェブサイトhttps://www.ligand.com/
企業コードLGND
上場日Nov 18, 1992
最高経営責任者「CEO」Mr. Todd C. Davis
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
137.16K
+0.89%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
44.37K
-1.04%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
15.72K
-7.77%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
9.35K
+14.86%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.86K
+21.40%
Dr. Martine Zimmermann, Pharm.D.
Dr. Martine Zimmermann, Pharm.D.
Independent Director
Independent Director
4.29K
+31.26%
Mr. Todd C. Davis
Mr. Todd C. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
137.16K
+0.89%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
44.37K
-1.04%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
15.72K
-7.77%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Captisol
13.46M
29.69%
Qarziba
5.44M
12.00%
Filspari
5.30M
11.69%
Kyprolis
4.72M
10.42%
Milestone
4.38M
9.67%
他の
12.02M
26.52%
データなし
事業別
地域別
事業別USD
会社名
収益
比率
Captisol
13.46M
29.69%
Qarziba
5.44M
12.00%
Filspari
5.30M
11.69%
Kyprolis
4.72M
10.42%
Milestone
4.38M
9.67%
他の
12.02M
26.52%
株主
更新時刻: Sat, Aug 23
更新時刻: Sat, Aug 23
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
13.55%
The Vanguard Group, Inc.
10.64%
Janus Henderson Investors
5.41%
Macquarie Investment Management
4.73%
State Street Global Advisors (US)
3.83%
他の
61.85%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
13.55%
The Vanguard Group, Inc.
10.64%
Janus Henderson Investors
5.41%
Macquarie Investment Management
4.73%
State Street Global Advisors (US)
3.83%
他の
61.85%
種類
株主統計
比率
Investment Advisor
58.71%
Investment Advisor/Hedge Fund
37.72%
Individual Investor
2.35%
Pension Fund
1.63%
Research Firm
1.22%
Bank and Trust
0.45%
Hedge Fund
0.45%
Sovereign Wealth Fund
0.11%
Insurance Company
0.04%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
535
19.71M
102.13%
-738.05K
2025Q1
554
19.82M
102.82%
-711.89K
2024Q4
546
19.28M
100.16%
-1.51M
2024Q3
543
19.17M
104.83%
-583.22K
2024Q2
527
18.31M
101.74%
-865.78K
2024Q1
520
17.60M
99.35%
-393.03K
2023Q4
527
16.97M
97.29%
-861.76K
2023Q3
515
17.24M
99.38%
-910.17K
2023Q2
526
17.09M
98.94%
-1.02M
2023Q1
528
16.47M
96.50%
-1.33M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
2.67M
13.86%
-26.33K
-0.97%
Mar 31, 2025
The Vanguard Group, Inc.
2.05M
10.63%
-29.89K
-1.44%
Mar 31, 2025
Janus Henderson Investors
1.03M
5.33%
+12.53K
+1.23%
Mar 31, 2025
Macquarie Investment Management
906.23K
4.7%
+21.85K
+2.47%
Mar 31, 2025
State Street Global Advisors (US)
727.13K
3.77%
-16.51K
-2.22%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
744.93K
3.86%
+21.91K
+3.03%
Mar 31, 2025
Congress Asset Management Company, LLP
642.71K
3.33%
+21.23K
+3.42%
Mar 31, 2025
Stephens Investment Management Group, LLC
607.22K
3.15%
-5.56K
-0.91%
Mar 31, 2025
Chicago Capital, LLC
554.52K
2.87%
+2.93K
+0.53%
Mar 31, 2025
Geode Capital Management, L.L.C.
464.45K
2.41%
+26.01K
+5.93%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Tue, Sep 2
更新時刻: Tue, Sep 2
銘柄名
比率
Invesco Pharmaceuticals ETF
3.45%
Virtus LifeSci Biotech Products ETF
2.21%
Franklin Genomic Advancements ETF
2.18%
SPDR S&P Pharmaceuticals ETF
2.12%
Invesco S&P SmallCap Health Care ETF
1.71%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.31%
iShares U.S. Pharmaceuticals ETF
1.25%
First Trust Multi-Manager Small Cap Opportunities ETF
0.8%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.77%
OneAscent Small Cap Core ETF
0.62%
詳細を見る
Invesco Pharmaceuticals ETF
比率3.45%
Virtus LifeSci Biotech Products ETF
比率2.21%
Franklin Genomic Advancements ETF
比率2.18%
SPDR S&P Pharmaceuticals ETF
比率2.12%
Invesco S&P SmallCap Health Care ETF
比率1.71%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
比率1.31%
iShares U.S. Pharmaceuticals ETF
比率1.25%
First Trust Multi-Manager Small Cap Opportunities ETF
比率0.8%
Pacer US Small Cap Cash Cows Growth Leaders ETF
比率0.77%
OneAscent Small Cap Core ETF
比率0.62%
配当金
過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
KeyAI